Clinical trial
Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming…
NCT00420316 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00420316 |
|---|---|
| Title | Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine. |
| Official title | To Assess Long-term Efficacy & Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine (Rotarix) in the Primary Vaccination Study (102247). |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Rotavirus |
| Intervention type | Biological |
| Interventions | Rotarix (primary vaccination study), Placebo (primary vaccination study) |
| Enrollment | 1,613 |
| Start date | Feb 12, 2007 |
| Primary completion | Aug 8, 2007 |
| Completion | Aug 8, 2007 |
| First posted | Jan 11, 2007 |
| Last update posted | Aug 28, 2018 |
| Countries | Finland |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: